Literature DB >> 15773823

Plasma nociceptin levels are reduced in migraine without aura.

C Ertsey1, M Hantos, G Bozsik, K Tekes.   

Abstract

It was demonstrated that both nociceptin, a novel opioid neuropeptide, and its receptor are present in trigeminovascular neurons. In an animal model nociceptin dose-dependently inhibited neurogenic dural vasodilatation. These results suggest that nociceptin may be involved in neurovascular headaches such as migraine. To test this hypothesis, we studied circulating nociceptin levels in 18 patients suffering from migraine without aura and in 24 controls. Headache-free migraineurs had significantly lower nociceptin levels than controls (5.79 +/- 1.82 vs. 9.74 +/- 2.43 pg/ml, P < 0.0001, Student's t-tests). Nociceptin levels were further reduced in six patients studied in the first 3 h of typical migraine attacks (1.04 +/- 0.17 pg/ml). Nociceptin levels correlated with the frequency of attacks in this group of migraineurs. Lower interictal nociceptin levels may contribute to a defective regulation of trigeminovascular neurons in migraineurs which might be important in the pain process of migraine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15773823     DOI: 10.1111/j.1468-2982.2004.00849.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  7 in total

1.  NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice.

Authors:  Katarzyna M Targowska-Duda; Akihiko Ozawa; Zachariah Bertels; Andrea Cippitelli; Jason L Marcus; Hanna K Mielke-Maday; Gilles Zribi; Amanda N Rainey; Brigitte L Kieffer; Amynah A Pradhan; Lawrence Toll
Journal:  Neuropharmacology       Date:  2020-03-06       Impact factor: 5.250

Review 2.  The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

Authors:  Jeffrey M Witkin; Michael A Statnick; Linda M Rorick-Kehn; John E Pintar; Michael Ansonoff; Yanyun Chen; R Craig Tucker; Roberto Ciccocioppo
Journal:  Pharmacol Ther       Date:  2013-11-01       Impact factor: 12.310

Review 3.  The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies.

Authors:  Lawrence Toll; Andrea Cippitelli; Akihiko Ozawa
Journal:  CNS Drugs       Date:  2021-05-31       Impact factor: 6.497

4.  Neuropeptide changes in an improved migraine model with repeat stimulations.

Authors:  Yichen Guo; Yawen Cheng; Jiaqi An; Yi Qi; Guogang Luo
Journal:  Transl Neurosci       Date:  2021-12-09       Impact factor: 1.757

5.  Increased nociceptive sensitivity and nociceptin/orphanin FQ levels in a rat model of PTSD.

Authors:  Yong Zhang; Priyam R Gandhi; Kelly M Standifer
Journal:  Mol Pain       Date:  2012-10-20       Impact factor: 3.395

6.  Exacerbated Headache-Related Pain in the Single Prolonged Stress Preclinical Model of Post-traumatic Stress Disorder.

Authors:  Yong Zhang; Kelly M Standifer
Journal:  Cell Mol Neurobiol       Date:  2020-09-15       Impact factor: 5.046

Review 7.  New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.

Authors:  Irene Simonetta; Renata Riolo; Federica Todaro; Antonino Tuttolomondo
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.